[Survival of children with recurrent medulloblastoma undergoing sequential therapy: an analysis of 101 cases].
- 1 February 2021
- journal article
- Vol. 23 (2), 164-168
Abstract
To study the clinical features of children with recurrent medulloblastoma (MB) and treatment regimens. A retrospective analysis was performed on 101 children with recurrent MB who were admitted to the hospital from August 1, 2011 to July 31, 2017. The children were followed up to July 31, 2020. The Kaplan-Meier method was used for survival analysis. The Cox regression model was used for multivariate regression analysis. Of the 101 children, 95 underwent remission induction therapy, among whom 51 had response, resulting in a response rate of 54%. The median overall survival (OS) time after recurrence was 13 months, and the 1-, 3-, and 5-year OS rates were 50.5%±5.0%, 19.8%±4.0%, and 10%±3.3% respectively. There was no significant difference in the 5-year OS rate between the children with different ages (< 3 years or 3-18 years), sexes, pathological types, or Change stages, between the children with or without radiotherapy before recurrence or re-irradiation after recurrence, and between the children with different times to recurrence (< 12 months or ≥ 12 months after surgery) (P > 0.05). There were significant differences in the 5-year OS rate between the children with or without reoperation after recurrence and between the children with different recurrence sites (P < 0.05). The children with reoperation after recurrence had a significantly longer survival time than those without reoperation (P=0.007), and the risk of death in children undergoing reoperation after recurrence was 0.389 times (95% confidence interval:0.196-0.774) that in children who did not undergo such reoperation. As for the recurrence of MB, although remission induction therapy again can achieve remission, such children still have a short survival time. Only reoperation can significantly prolong survival time, and therefore, early reoperation can be considered to improve the outcome of children with recurrent MB.Keywords
This publication has 21 references indexed in Scilit:
- Treatment of recurrent primitive neuroectodermal tumors (PNET) in children and adolescents with high-dose chemotherapy (HDC) and stem cell support: results of the HITREZ 97 multicentre trialJournal of Neuro-Oncology, 2014
- Treatment of Children With Central Nervous System Primitive Neuroectodermal Tumors/Pinealoblastomas in the Prospective Multicentric Trial HIT 2000 Using Hyperfractionated Radiation Therapy Followed by Maintenance ChemotherapyInternational Journal of Radiation Oncology*Biology*Physics, 2014
- Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium StudyClinical Cancer Research, 2013
- Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experienceChild's Nervous System, 2013
- Molecular subgroups of medulloblastoma: the current consensusActa Neuropathologica, 2011
- Efficacy of High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Relapsed Medulloblastoma: A Report on The Korean Society for Pediatric Neuro-Oncology (KSPNO)-S-053 StudyJournal of Korean Medical Science, 2010
- Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastomaNeuro-Oncology, 2008
- Phase II Trial of Irinotecan in Children With Refractory Solid Tumors: A Children's Oncology Group StudyJournal of Clinical Oncology, 2007
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- An Operative Staging System and a Megavoltage Radiotherapeutic Technic for Cerebellar MedulloblastomasRadiology, 1969